From weight-loss brand to Britain's weight-management partner for life.

The opportunity. The medication era did not end weight management. It split one market into three: people who will not or cannot take the medications, people currently on them with little nutritional or human support, and people coming off them facing the regain the clinical literature predicts. The 1:1 Diet competes in the first today, and it is the only one of the three that is shrinking.

The thesis. Three doors, one brand: Classic for people avoiding medication, Companion for people on it, and For Life for people coming off it. One storefront, one attribution spine, one consultant network earning from all three.

The moat. Roughly six thousand trained one-to-one consultants across the UK and Ireland, forty years of brand trust, owned manufacturing in Corby, employee ownership and a strong balance sheet. In a market whose defining problem is now what happens between and after prescriptions, that network is not a legacy cost. It is the asset the era rewards.

The date. January 2027, the first New Year diet season of the pill era. The three doors are either in market for it, with founding consultants certified and the storefront live, or the season is fought with last era's weapons.

How it starts. With a fixed-scope Strategy Blueprint: several weeks of joint work on your own data producing the operating design, the full financial case and a go or no-go decision with nothing hidden. Investment is shared in the Blueprint conversation, against your own modelled return.

Every company in weight management has spent three years watching the same storm. In the year to early 2025, 1.6 million adults in Great Britain used weight-loss medication, and a further 3.3 million said they were interested in starting (UCL, BMC Medicine, January 2026). Monthly sales of weight-loss injections rose roughly fivefold in a single year, to 2.5 million packs by July 2025 (The Telegraph). WeightWatchers, the most famous brand in the category's history, went through Chapter 11 bankruptcy in 2025. Jenny Craig had already gone in 2023.

Then, in the space of nine weeks this summer, the storm changed shape. In June the medicines regulator approved the first pill version of the new weight-loss medicines, and by early July it was on sale in high-street pharmacies from £79 a month. In August a second, easier-to-manufacture pill was approved in Britain before anywhere else in Europe, with its NHS evaluation scheduled for November. The needle, the strongest brake on adoption, is leaving the story. The pill era has started, and the first New Year diet season it will touch is January 2027.

It is tempting to read all of this as the end of the traditional weight-management company. We read the same evidence and reach a different conclusion, for one reason the headlines consistently miss: the medications have a revolving door. Around half of the people who start them stop within a year, and the clinical data on what happens next is unambiguous. In the largest extension study, people who stopped regained roughly two thirds of the weight they had lost within twelve months (STEP 1 extension, Diabetes, Obesity and Metabolism). The National Institute for Health and Care Excellence has responded by recommending that anyone coming off weight-loss medication receive structured support for at least a year afterwards. The regulator has, in effect, described a new national market: post-medication maintenance. Almost nobody is building for it.

This document is about how The 1:1 Diet becomes the company that does, without abandoning what it already is, and why the assets you have spent forty years building, above all your consultants, are precisely the assets the medication era rewards.

The old weight-management market was one market: people who wanted to lose weight chose between diets. The medication era has split it into three, each with different needs and different economics.

The first market is the untreated: people who will not inject, cannot afford treatment, are not eligible, or simply prefer a food-based approach. This is the market The 1:1 Diet serves today, and price is moving in your favour within it: the leading private injectable's list price rose by as much as 170 percent from September 2025 (reported across the trade press), putting typical private treatment above £200 a month, while NHS access remains rationed to a fraction of the eligible population for years to come (NHS England interim commissioning guidance: roughly 220,000 patients over three years against 3.4 million eligible). A structured programme at around £60 a week with a human being beside you is a genuine alternative, and it deserves to be marketed as one. But this market is shrinking as the medications get easier and cheaper, and a strategy built only here is a strategy of managed decline.

The second market is the treated: more than one and a half million people, overwhelmingly private patients, most of them navigating reduced appetite, protein and micronutrient shortfalls, and muscle-loss concerns with little or no structured support. The UCL study's authors flagged exactly this gap. Food companies have noticed: Nestlé, Abbott and Herbalife all launched medication-companion nutrition lines in 2024. What none of them has is a human support network.

The third market is the discontinued, and it is the one the medications themselves manufacture. Apply the discontinuation and regain evidence to the current user base and the arithmetic is stark: hundreds of thousands of people each year, stepping off medication, facing the regain the clinical literature predicts, with NICE now formally recommending a year of structured support that the NHS is not resourced to provide at scale. This is a maintenance market, not a diet market. It wants weekly human accountability, portion-controlled nutrition, habit change and dignity. It is, almost line for line, a description of what a 1:1 consultant does.

Three markets. You currently compete in one. The plan in this document competes in all three with one brand, one storefront and one community engine.

Before any recommendation, it is worth being precise about what this company brings to the medication era, because from the outside the list is more valuable than the category's mood suggests.

First, the network. Roughly six thousand trained, self-employed consultants across the UK and Ireland (as publicly reported in 2024), each delivering weekly one-to-one support, most of them living proof of the programme themselves. Telehealth prescribers have apps and call centres. Slimming World has groups. Nobody else in Britain has thousands of accountable one-to-one human coaches with local presence and lived experience. In a market whose defining clinical problem is now what happens between and after prescriptions, that network is not a legacy cost. It is the moat.

Second, the brand and the factory. Forty years of continuous operation, a name that generations of British dieters know, and your own manufacturing in Corby, which means product economics, formulation control and launch speed that brand-only competitors cannot match. Third, the structure: employee ownership since 2014 and a balance sheet that public filings show carries around £14 million in cash. You are not a distressed asset. You are a well-capitalised company facing a strategic inflection with the means to act.

And fourth, the thing an outside adviser should say plainly: your leadership has already read the moment correctly. The support programme on your website, positioned carefully as a companion rather than a competitor to medication. PortionIQ, a protein-forward companion range launched in 2026 with genuine direct-to-consumer commerce. Serenova. The dieter app. These are the right instincts, executed as separate initiatives. What the group does not yet have is the connective tissue: one commerce engine where every digital sale strengthens a consultant instead of orbiting past her, one attribution spine across brands, one activation system that turns forty years of successful dieters into next year's growth. Building that connective tissue is what this document proposes.

The cautionary ledger first. Jenny Craig shut its doors in May 2023 and survives only as an e-commerce label, its human network gone. WeightWatchers went through Chapter 11 in May 2025, wiping out $1.15 billion of debt; its clinical telehealth arm is growing fast, but from a small base, and the company's overall revenues are still shrinking. Most instructive of all is Medifast, the American analogue of a coach-based weight-loss direct seller: it partnered with a telehealth prescriber in 2023, and its latest quarterly results still showed revenue down by more than a third year on year with its coach base nearly halved. The lesson is not that these companies acted; it is what they bolted the action onto. A prescription pathway added to an undefended model does not stop the bleeding, because prescribing is not a moat. Support is.

The encouraging ledger: Noom built a taper-off guarantee around the regain problem and made post-medication support a product. Herbalife, Nestlé and Abbott validated companion nutrition as a category in a single year. Avon's UK business has shown that a direct-selling field can be carried into an omnichannel world when the field is treated as the beneficiary of every new channel. And closest to home: Slimming World launched its in-person medication-support programme in May 2026, publicly claiming the position of the largest in-person support organisation for people on these medications. That should be read two ways at once. It validates every argument in this document. And it starts a clock, because Slimming World has groups and goodwill, but it does not have one-to-one delivery, its own products, its own factory, or a commerce platform, and for the next year or so, neither incumbency nor infrastructure decides who owns the maintenance era. Speed does.

The acquisition device already exists: the £9.99 taster pack, the one product on the main site a customer can actually buy today, complete with the promise that a consultant will be in touch. That mechanic, a low-risk paid trial that hands a warm customer to a human, is the front door for all three propositions, and it becomes the referral currency of chapter 10: the thing a successful loser gives a friend.

Door one keeps its range as is. Door two draws on PortionIQ and the higher-protein end of the existing catalogue, organised into a companion selection calibrated for suppressed appetites: fewer, denser, protein-forward products with clear daily structure. Door three is the genuinely new edit: a maintenance range assembled substantially from existing SKUs, portioned for one or two products a day rather than full replacement, bundled into a monthly subscription box that arrives with the consultant check-in built into its rhythm. Priced as a membership in the tens of pounds a month, it reframes the company's economics from twelve-week journeys to multi-year relationships.

Own manufacturing in Corby turns all of this from a supplier negotiation into a production schedule, and formulation control means the maintenance range can be genuinely calibrated rather than relabelled. Few strategic pivots in consumer goods come with the factory already owned.

The structural promise comes first, in plain words: nothing in this programme changes existing consultant terms. Not margins, not team arrangements, not wholesale pricing, not qualifications. The programme adds earning lines: attributed digital sales, subscription income that follows the customer she earned, referral flow from the loop, and a new certification, the 1:1 For Life maintenance accreditation, that makes the most experienced consultants the senior practitioners of the company's next chapter.

The second principle is that leaders go first. Before anything launches publicly, the recognised names of the field, the award winners and the long-tenured, are invited in as founding members: consulted on the design, first through certification, first with storefronts, visibly recognised inside the programme. Their questions get answered in private before the field asks them in public, and their endorsement, freely given because the economics deserve it, is the launch plan.

The third is honest communication about the direct channel. Digital customers who arrive with no consultant connection are matched to one, or their value feeds a transparent house pool, and the field can see the mechanism. The contrast with the industry's bypass stories, where fields discovered e-commerce as competition rather than income, should be drawn explicitly in field communications, because the difference is the design.

This chapter is a named workstream with the same standing as engineering, and it is delivered with the company's own leadership voices carrying it, in the same one-to-one spirit the brand is named for.

The new storefront makes the catalogue transparent: prices visible, products explorable, the three doors of chapter 5 presented as journeys with honest guidance about which fits whom. The taster pack and starter bundles are buyable in the moment the decision is made; the subscription options for Companion and For Life sit natively on product pages; verified reviews, collected and displayed inside the authenticity rules the law now demands, do the reassurance work this category depends on. At checkout, the customer chooses or is matched to her consultant, which is the moment the brand's difference becomes tangible: the parcel comes with a person.

Ireland is served natively in euro alongside sterling. The consultant portal and app journeys plug into the same commerce layer, so a consultant reordering for her clients, a dieter reordering for herself, and a maintenance member's monthly box all run on one engine with one attribution spine, and the group's existing direct-commerce experience is built on rather than duplicated.

The brand work is therefore extension, not reinvention. The story widens from before-and-after to for-life: the same photography and warmth, applied to year three as proudly as to week twelve; maintenance stories as the new flagship genre; consultants as the visible heroes of the medication era rather than survivors of it. The companion and maintenance propositions are presented in the careful, medication-agnostic language the rules require, and that discipline is turned into an asset: a claims-safe messaging and content library, covering weight-control claims, testimonial substantiation and the strict boundaries around prescription products, distributed through the platform so that six thousand voices can be loud safely.

That last point deserves its own sentence: in today's enforcement environment, the brand's distributed voice is either its greatest liability or its greatest reach advantage, and the only thing that decides which is the system behind it.

Email and SMS come first because the infrastructure is already installed and ready to be put to work: the tooling exists on both the site and the app today, waiting for the capture and journeys that turn it into an audience. Every visitor, taster-pack buyer, quiz-taker and booking becomes an owned relationship: welcome journeys per door, replenishment rhythms tuned to pack sizes, maintenance check-in sequences that mirror the consultant calendar, and win-back journeys for the lapsed decades.

Social carries the story: the official channels concentrated where the audiences are, a deliberate entry into short-form video where the category's conversation now happens, and, above all, the consultant storefront ecosystem of chapter 10 as the long tail that no competitor can imitate. Paid amplifies what organically proves itself, aimed with particular intent at the post-medication search and social spaces where demand is demonstrably present and competition is demonstrably thin.

Search is the patient build: owning the maintenance conversation in plain-language content, defending brand terms that competitors openly conquest today, and earning the category terms where the brand deserves to appear and does not yet. And marketplace policy becomes a decision rather than a drift: branded product circulates on resale platforms today without the company's hand on price, freshness or presentation; an official channel policy, chosen deliberately market by market, protects both the brand and the consultants' economics.

Delivery is by a dedicated pod: strategy, platform engineering, lifecycle and CRM, creator and community management, paid media and creative, with direct-selling compliance design across all of it, drawn from a team with two decades of direct-to-consumer operating history.

The commercial philosophy matters more than any number, and it is simple: fees that are modest against the in-house alternative of chapter 7, and a success share taken only on the new business the engine creates. On the existing business, the consultant network's current revenue, the legacy programme, everything four decades built, we take nothing and claim nothing. The precise structure is a conversation for the Blueprint stage; the principle is not: partners with skin in the game behave differently from vendors, and we ask to be judged that way.

The engagement starts with a Strategy Blueprint: a fixed-scope piece of joint work over a small number of weeks, in which the three-door proposition is tuned to your data, the attribution design is specified against your systems through the question list of chapter 8, the consultant economics are modelled with your real numbers, the compliance framework is drafted, and the rollout calendar is fixed. It ends with a decision document the board can accept or decline with complete information, and it is structured so that a group that proceeds sees the Blueprint investment recognised in what follows.

From there, commitment is phased: build, pilot with founding consultants, launch, and scale, with the managed-services layer growing as the revenue it manages grows. Investment for each phase is shared in the Blueprint conversation, where it can be presented against your own modelled return rather than as an abstraction, and where every line of it can be compared honestly with the in-house and agency alternatives this document has already costed.

The immediate decision is deliberately small: a Blueprint, a pilot with your best consultants, a storefront, a first uncontested market. What it buys, if the work proves itself, is large: a documented, repeatable engine, proposition, attribution, activation, compliance, that extends to Ireland natively, to the distributor markets on the same rails, and across a group whose newer brands can share the spine.

That last point is worth a moment, because it is where this programme and the group's wider strategy lock together. The group already holds the two halves of a resilient future: an industrial half, where the factory and the contract-manufacturing arm prosper on the medication era's demand for exactly what Corby makes, and a consumer half, where this document's three doors turn the consultant network and the newer brands toward the markets the era is creating. The engine proposed here is built once and serves the whole consumer half: the same storefront, attribution and subscription rails can carry PortionIQ's companion range and Serenova's range as naturally as they carry The 1:1 Diet, each brand keeping its own identity on shared infrastructure. One investment, several ways to win, and no single brand carrying the whole weight of the future. And it resolves the identity question this era has forced on every company in the category. Not a diet brand defending a shrinking definition of itself, but Britain's weight-management partner for life, with six thousand human reasons to believe it.

The medication era will have winners. The evidence in this document says the assets to be one are already in Corby. What they need is the engine, and the engine is what we build.